Nothing Special   »   [go: up one dir, main page]

AR105112A1 - Compuestos de aminopiridina sustituida con heteroarilo - Google Patents

Compuestos de aminopiridina sustituida con heteroarilo

Info

Publication number
AR105112A1
AR105112A1 ARP160101891A ARP160101891A AR105112A1 AR 105112 A1 AR105112 A1 AR 105112A1 AR P160101891 A ARP160101891 A AR P160101891A AR P160101891 A ARP160101891 A AR P160101891A AR 105112 A1 AR105112 A1 AR 105112A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
fluoroalkyl
hydroxyalkyl
cycloalkyl
Prior art date
Application number
ARP160101891A
Other languages
English (en)
Inventor
Rao Polimera Subba
Kumar Sistla Ramesh
Sarkunam Kandhasamy
Ratna Kumar Sreekantha
Reddy Paidi Venkatram
Kesavan Nair Satheesh
Kantheti Durgarao
Wu Hong
B Santella Joseph
Murugesan Natessan
E Macor John
Hynes John
s gardner Daniel
V Duncia John
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR105112A1 publication Critical patent/AR105112A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) o una sal de aquel, en donde: HET es un heteroarilo seleccionado de oxazolilo, pirazolilo, imidazo[1,2-b]piridazin-3-ilo y pirazolo[1,5-a]pirimidin-3-ilo, en donde el heteroarilo está unido al grupo piridinilo en el compuesto de la fórmula (1) mediante un átomo del anillo de carbono en el heteroarilo, y en donde el heteroarilo se sustituye con 0 a 2 Rᵇ; cada Rᵇ se selecciona independientemente de -H, F, Cl, -CN, -NH₂, C₁₋₃ alquilo, C₁₋₂ fluoroalquilo, C₁₋₃ alcoxi, C₃₋₆ cicloalquilo, -NH(C₁₋₃ alquilo), -NH(C₁₋₄ hidroxialquilo), cianofenilo, piridinilo e hidroxipirrolidinilo; R¹ es (i) C₃₋₆ alquilo sustituido con 1 a 4 sustituyentes seleccionados independientemente de F, -CN, -OH, -OCH₃, -OCD₃, -NHC(O)(C₁₋₃ alquilo), -S(O)₂(C₁₋₃ alquilo) y C₁₋₂ fluoroalcoxi; y (ii) -(CRʸRʸ)₁₋₃Rˣ o -(CH₂)₁₋₃C₍O₎Rˣ, en donde Rˣ es fenilo, oxetanilo, tetrahidropiranilo, morfolinilo, piperidinilo, imidazolilo; piridinilo, tiofenilo o C₄₋₆ cicloalquilo, cada uno sustituido con 0 a 3 sustituyentes seleccionados independientemente de F, Cl, -OH, C₁₋₃ alquilo, C₁₋₂ alcoxi y -S(O)₂NH₂; (iii) C₄₋₆ cicloalquilo sustituido con 0 a 2 sustituyentes seleccionados independientemente de -OH, C₁₋₄ hidroxialquilo, C₁₋₃ alcoxi, -(CH₂)₁₋₃O(C₁₋₃ alquilo), -C(O)NH(C₁₋₄ alquilo), -C(O)NH(C₃₋₆ cicloalquilo), -N(C₁₋₃ alquilo)₂, -NHC(O)(C₁₋₃ alquilo), -NHC(O)O(C₁₋₃ alquilo) y -NHC(O)(C₁₋₄ hidroxialquilo); (iv) tetrahidrofuranilo, tetrahidropiranilo, piperidinilo, piperazinilo, pirrolilo, pirazolilo, imidazolilo o triazolilo, cada: uno sustituido con 0 a 2 sustituyentes seleccionados independientemente de C₁₋₄ hidroxialquilo, S(O)₂(C₁₋₃ alquilo), -CH₂C(O)NH(C₁₋₃ alquilo), -CH₂C(O)NH(C₁₋₆ hidroxialquilo), -CH₂C(O)NH(C₁₋₆ fluoroalquilo) y -CH₂C(O)NH(C₁₋₆ hidroxi-fluoroalquilo); o (v) 1-oxa-7-azaspiro[3.5]nonanilo; cada Rʸ es independientemente H, F o -OH; y R³ es: (i) C₂₋₅ alquilo, C₂₋₅ fluoroalquilo, C₂₋₅ hidroxialquilo, -(CH₂)₁₋₃Rᶻ, -CH(CH₃)Rᶻ o -CH(CH₂OH)CH₂Rᶻ, en donde Rᶻ es C₄₋₆ cicloalquilo, oxetanilo, tetrahidrofuranilo, tetrahidropiranilo o fenilo, cada uno sustituido con 0 a 1 sustituyente seleccionado de -OH y -CH₃; (ii) C₃₋₆ cicloalquilo sustituido con 0 a 3 sustituyentes seleccionados independientemente de F, Cl, -CN, -OH, C₁₋₃ alquilo, C₁₋₃ fluoroalquilo, C₁₋₄ hidroxialquilo, C₁₋₄ alcoxi, -C(O)NH₂, -C(O)NH(C₁₋₃ alquilo) y -C(O)(C₁₋₃ fluoroalquilo); (iii) oxetanilo, tetrahidrofuranilo, tetrahidropiranilo, pirrolidinilo, piperidinilo, pirazolilo, tiazolilo, biciclo[1.1.1]pentanilo, biciclo[2.2.1]heptanilo o 4,5,6,7-tetrahidropirazolo[1,5-a]pirazinilo, cada uno sustituido con 0 a 2 sustituyentes seleccionados independientemente de F, -OH, C₁₋₄ alquilo, C₁₋₃, hidroxialquilo, C₁₋₄ fluoroalquilo, -CH₂(C₃₋₆ cicloalquilo), -(CH₂)₁₋₃O(C₁₋₃ alquilo), -C(O)(C₁₋₃ fluoroalquilo), -S(O)₂(C₁₋₃ alquilo), C₃₋₆ cicloalquilo, C₃₋₆ fluorocicloalquilo, oxetanilo, tetrahidrofuranilo, tetrahidropiranilo, pirimidinilo, fluoropirimidinilo y metoxipirimidinilo; o (iv) fenilo sustituido con 0 a 3 sustituyentes seleccionados independientemente de F, Cl, -CN, -OH, -C(O)NH₂, -C(O)NH(C₁₋₃ alquilo) y -C(O)(C₁₋₃ fluoroalquilo).
ARP160101891A 2015-06-24 2016-06-23 Compuestos de aminopiridina sustituida con heteroarilo AR105112A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1876DE2015 2015-06-24

Publications (1)

Publication Number Publication Date
AR105112A1 true AR105112A1 (es) 2017-09-06

Family

ID=56297140

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101891A AR105112A1 (es) 2015-06-24 2016-06-23 Compuestos de aminopiridina sustituida con heteroarilo

Country Status (9)

Country Link
US (1) US10618903B2 (es)
JP (1) JP6720355B2 (es)
KR (1) KR102641263B1 (es)
CN (1) CN109641906B (es)
AR (1) AR105112A1 (es)
ES (1) ES2783852T3 (es)
TW (1) TW201713655A (es)
UY (1) UY36749A (es)
WO (1) WO2016210036A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
BR112020025202A2 (pt) * 2018-06-15 2021-03-09 Galapagos Nv Compostos e composições farmacêuticas dos mesmos para o tratamento de doenças
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CA3105795C (en) * 2018-08-13 2024-01-16 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
KR102659550B1 (ko) * 2018-08-13 2024-04-23 길리애드 사이언시즈, 인코포레이티드 Irak4 억제제로서의 피롤로[1,2-b]피리다진 유도체
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110862375B (zh) 2018-08-27 2022-10-25 深圳铂立健医药有限公司 吡唑化合物及其药物组合物和应用
WO2021158495A1 (en) * 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
CN112430632B (zh) * 2020-11-18 2022-09-13 上海合全药物研发有限公司 2-((反式)-4-氨基环己烷基)异丙醇的制备方法
CN116425757A (zh) * 2022-01-13 2023-07-14 浙江同源康医药股份有限公司 多环类化合物及其用途
WO2023226976A1 (zh) * 2022-05-24 2023-11-30 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825190B2 (en) 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
ATE530530T1 (de) 2002-06-28 2011-11-15 Astellas Pharma Inc Diaminopyrimidincarbonsäureamidderivat
DE602004021558D1 (de) 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
CA2531401A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US8273759B2 (en) 2007-06-08 2012-09-25 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
WO2010144647A1 (en) 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2493863B1 (en) 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
WO2012132656A1 (ja) 2011-03-29 2012-10-04 日本ゼオン株式会社 熱伝導性感圧接着剤組成物、熱伝導性感圧接着性シート状成形体、これらの製造方法、及び電子部品
WO2012149567A1 (en) 2011-04-29 2012-11-01 Mount Sinai School Of Medicine Kinase inhibitors
WO2013106641A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
EP2802577B1 (en) 2012-01-13 2017-03-01 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013106612A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
WO2014074657A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
SG11201503397YA (en) 2012-11-08 2015-05-28 Bristol Myers Squibb Co Heteroaryl substituted pyridyl compounds useful as kinase modulators
CN104781252B (zh) 2012-11-08 2017-11-17 百时美施贵宝公司 用作IL‑12、IL‑23和/或IFNα应答调节剂的被烷基‑酰胺取代的吡啶化合物
AR098991A1 (es) 2014-01-03 2016-06-22 Bristol Myers Squibb Co Compuestos de nicotinamida sustituida con heteroarilo
WO2016144844A1 (en) * 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Carboxamide inhibitors of irak4 activity
US10202390B2 (en) 2015-06-24 2019-02-12 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds

Also Published As

Publication number Publication date
US10618903B2 (en) 2020-04-14
WO2016210036A1 (en) 2016-12-29
TW201713655A (zh) 2017-04-16
UY36749A (es) 2016-12-30
JP2019522656A (ja) 2019-08-15
JP6720355B2 (ja) 2020-07-08
ES2783852T3 (es) 2020-09-18
CN109641906B (zh) 2021-10-01
CN109641906A (zh) 2019-04-16
KR102641263B1 (ko) 2024-02-26
US20190292191A1 (en) 2019-09-26
KR20190019187A (ko) 2019-02-26

Similar Documents

Publication Publication Date Title
AR105112A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR105114A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR101174A1 (es) Imidazopirazinas como inhibidores de lsd1
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
AR101175A1 (es) Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
AR110405A1 (es) Compuestos
AR094494A1 (es) Pirrolopirimidinas sustituidas, sus composiciones, y sus métodos de tratamiento
ES2721031T3 (es) Compuestos de dihidroisoquinolinona sustituidos
RU2019107667A (ru) Спироциклические соединения
AR091628A1 (es) 7h-pirrolo[2,3-d]pirimidinas 4-(amino-substituidas) como inhibidores de lrrk2
AR100645A1 (es) Derivados de pirazolo-pirimidina
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
JP2014523857A5 (es)
AR094982A1 (es) Derivados de triazolo[4,5-d]pirimidina
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
AR089424A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR106865A1 (es) Piridinas sustituidas y métodos de uso
JP2018538264A5 (es)
AR092973A1 (es) Benzamidas
AR095267A1 (es) Compuestos inhibidores de la fosfodiesterasa del tipo 10a

Legal Events

Date Code Title Description
FB Suspension of granting procedure